학술논문

Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.
Document Type
article
Source
PloS one. 16(12)
Subject
Cancer
General Science & Technology
Language
Abstract
[This corrects the article DOI: 10.1371/journal.pone.0054014.].